Atterocor’s Adrenal Cancer Bid: Victory Where IGF-1s Couldn’t?

Climbing into the ring with one of the harder – albeit rare – cancers to beat, Atterocor Inc. started a Phase I trial with ATR-101, designed to selectively cause apoptosis in adrenal cell carcinoma (ACC).